Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

Funding for this conference was made possible in part by 1R13AI136762-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

The conference was supported by Gilead, which provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 12 of 12
Opening Plenary: Planning for Success (and the Challenges Ahead)
Welcome to HIVR4P 2018
Jose AlcamĂ­
Instituto de Salud Carlos III, Spain
Desmond Tutu Award for HIV Prevention and Human Rights
Georgia Tomaras
Duke University, United States
HIV Vaccines: Where Are We and What Next?
Linda-Gail Bekker
Desmond Tutu HIV Centre, University of Cape Town, South Africa
Novel Trial Designs for a Complex Environment
Sheena McCormack
MRC Clinical Trials Unit at UCL, United Kingdom
Ending the HIV/AIDS Pandemic: The Critical Role of HIV Prevention Science
Anthony Fauci
National Institute of Allergy and Infectious Diseases, NIH, United States
The Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy
Manju Chatani-Gada
AVAC, United States
HIVR4P 2018 Scholars
Mike Chirenje
University of Zimbabwe, Zimbabwe
from HIV Research for Prevention 2018 on 22 October 2018 16:00-18:00
Plenary 02: What Happens First: Understanding Susceptibility, Transmission and Early Infection
Visualizing HIV Transmission and Prevention
Thomas Hope
Northwestern University, United States
First Responders: What Early Infection Teaches About Prevention and Functional Cure Strategies
Thumbi Ndung’u
University of KwaZulu-Natal, South Africa
Untangling Hormonal Impacts on the Vaginal Microbiome and HIV Acquisition Risk
Sharon Achilles
University of Pittsburgh, United States
from HIV Research for Prevention 2018 on 23 October 2018 08:30-10:00
Plenary 03: The Future is Now: Next Steps in Developing New Prevention Options
Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis
Raphael Landovitz
UCLA Center for Clinical AIDS Research & Education, United States
On-demand Topical Agents for HIV Pre-exposure Prophylaxis
Craig Hendrix
Johns Hopkins University, United States
Vaccine Design 2.0: The Pipeline Novel HIV-1 Envelope Proteins to Induce Neutralizing Antibodies
Rogier Sanders
Amsterdam University Medical Centers (Amsterdam UMC), University of Amsterdam, Netherlands
from HIV Research for Prevention 2018 on 24 October 2018 08:30-10:00
Closing Plenary: Putting It Together: Strategies to End the Epidemic
Multi-disease Approaches to Combination Prevention - Insights from Rural East Africa
Diane Havlir
University of California at San Francisco, United States
Implementing a Multi-disciplinary Prevention Revolution
Maureen Luba
Centre for the Development of People (CEDEP), Malawi
The Impact of Prevention Strategies on HIV Incidence in a Community Center
Michael Meulbroek
BCN Checkpoint, Spain
A Path Forward for HIV Vaccines
John Mascola
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States
Closing Remarks and Handover to 2020
Susan Buchbinder
San Francisco Department of Public Health, United States
from HIV Research for Prevention 2018 on 25 October 2018 15:00-16:30
Opening Plenary: Get It and Forget It: Long-acting HIV Prevention
Welcome to HIVR4P 2016
Thomas Hope
Northwestern University, United States
The European Union's Research Strategy: Making an Impact on the HIV Epidemic
Ruxandra Draghia-Akli
European Commission, Belgium
Update on the Global HIV Vaccine Enterprise
William Snow
Global HIV Vaccine Enterprise
Congratulations to the 2016 Scholars
Maureen Goodenow
NIH Associate Director for AIDS Research and Director, Office of AIDS Research, United States
ART Prevents HIV Transmission: What Happens Next?
Myron Cohen
University of North Carolina, United States
Overview of Humoral and Cellular Immune Responses to HIV Vaccination
Georgia Tomaras
Duke University, United States
HIV Prevention Science in 2016: New Weapons in the Arsenal
Anthony Fauci
National Institute of Allergy and Infectious Diseases, NIH, United States
from HIV Research for Prevention 2016 on 17 October 2016 16:00-18:00
Plenary 02: Unraveling the Mysteries of HIV Transmission
HIV Transmission Dynamics
Deenan Pillay
Africa Health Research Institute, South Africa
Mechanisms of HIV Transmission: Implications for Prevention
Julie Overbaugh
Fred Hutchinson Cancer Research Center, United States
Providing Prevention Where It Matters Most: Data-informed Targeting of HIV Prevention and Care
Patrick Sullivan
Emory University Rollins School of Public Health, United States
from HIV Research for Prevention 2016 on 18 October 2016 08:30-10:00
Plenary 03: Which Way Is Forward: Emerging Challenges and Opportunities
Progress in Neutralizing Antibody-based HIV Vaccine Design
Dennis Burton
The Scripps Research Institute, United States
A View from the Ground
Noel Gordon
Human Rights Campaign, United States
Rings and Things
Sharon Hillier
University of Pittsburgh, United States
from HIV Research for Prevention 2016 on 19 October 2016 08:30-10:00
Closing Plenary: Bring It On: Delivering Combination Prevention
Introduction and Tribute to Ward Cates
Myron Cohen
University of North Carolina, United States
Sexual and Reproductive Health Over a Lifetime: Ward Cates' Contribution
Helen Rees
Wits Reproductive Health and HIV Institute, South Africa
From Research to Implementation: Delivery and Rollout
Deborah Birx
Office of the U.S. Global AIDS Coordinator, United States
Control of the HIV Epidemic: The Requirement for Effective Prevention
Emilio Emini
Bill & Melinda Gates Foundation, United States
Desmond Tutu Award for HIV Prevention and Human Rights
Nelly Mugo
Kenya Medical Research Institute (KEMRI), Kenya
Omu Falobi Award
Manju Chatani
AVAC, United States
Closing Remarks
Jeanne Marrazzo
University of Alabama at Birmingham School of Medicine, United States
Closing Remarks
Lynn Morris
National Institute for Communicable Diseases of the NHLS, South Africa
from HIV Research for Prevention 2016 on 20 October 2016 16:30-18:30
Opening Plenary: State of the Art Biomedical Prevention in 2014
Welcome to HIV R4P 2014
Helen Rees
on behalf of 2014 Co-Chairs
Desmond Tutu Award for HIV Prevention and Human Rights
Helen Rees
Keynote Address
Mrs GNM Pandor
MP, Minister of Science and Technology, South Africa
Congratulations to the 2014 Scholars
Jack Whitescarver
NIH Associate Director for AIDS Research and Director, Office of AIDS Research, United States
Prospects for an Antibody-based HIV Vaccine
Lynn Morris
National Institute for Communicable Diseases of the NHLS, Johannesburg, South Africa
Advances in Antiretroviral-Based Prevention Research
Jared Baeten
University of Washington, Seattle, WA, United States
Comprehensive HIV Prevention: Synergy Between Vaccine and Non-Vaccine Modalities
Anthony Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
from HIV Research for Prevention 2014 on 28 October 2014 08:15-10:30
Plenary 02: Targeting Biomedical Preventions to Different At-Risk Populations
Tailoring Biomedical Preventive Interventions for Key Populations: Towards Safety, Efficacy, Effectiveness
Chris Beyrer
Johns Hopkins Bloomberb School of Public Health, Baltimore, MD, United States
Working with Special Populations within HIV Prevention Intervention Programs and Trials
Bridget Haire
University of New South Wales, Sydney, Australia
Tailoring Interventions to Different Populations
Pontiano Kaleebu
MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
from HIV Research for Prevention 2014 on 29 October 2014 08:30-10:00
Plenary 03: Importance of Mucosa in Prevention Research
Utilizing NHP Models to Understand Mucosal HIV Transmission and Dissemination
Jake Estes
Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States
Genital Inflammation and HIV Risk in Prevention Research
Jo-Ann Passmore
University of Cape Town, Cape Town, South Africa
Mucosal Immune Assays in HIV Vaccine Clinical Trials
Omu Anzala
KAVI - Institute of Clinical Research (KAVI-ICR), University of Nairobi, Nairobi, Kenya
from HIV Research for Prevention 2014 on 30 October 2014 08:30-10:00
Closing Plenary: Mind the Gap: Bridging from Trial Success to Access
Keynote Address
The Honourable Minister of Health Dr Aaron Pakishe Motsoaledi
South Africa
Translating "Controlled" Trial Results to the Cities & Villages of Africa: Past, Present, & Future
Douglas Shaffer
Office of the U.S. Global AIDS Coordinator, U.S. Department of State, Washington, DC, United States
Scaling-up HIV Prevention Science from the Laboratory to the Village
Alex Coutinho
Infectious Diseases Institute, Kampala, Uganda
Antiretrovirals for Preventions
Glenda Gray
University of the Witwatersrand, Johannesburg, South Africa
2014 Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy
Recipient: Oyelakin Taiwo Oladayo (posthumously)
Award presented by:
Manju Chatani-Gada, AVAC
Award accepted by:
Olayide Akanni, JAAIDS
Closing Remarks and Handover to 2016
Robin Shattock
Imperial College, London, United Kingdom
Nelly Mugo
Kenya Medical Research Institute (KEMRI), Kenya
Lynn Morris
National Institute for Communicable Diseases, South Africa
Thomas Hope
Northwestern University, United States
Jeanne Marrazzo
University of Washington, United States
from HIV Research for Prevention 2014 on 31 October 2014 10:30-12:30
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 12 of 12